The Pandol Laboratory at the Cedars-Sinai Pancreatic Research Program is dedicated to establishing and maintaining the leading international research area at Cedars-Sinai for advancing the prevention, early diagnosis and treatment of pancreatic diseases. Pancreatic cancer, pancreatitis and diabetes are disorders with life-threatening consequences for patients and broad-reaching repercussions for their family members and friends. Each year pancreatic cancer is diagnosed in 250,000 patients worldwide (more than 40,000 in the U.S.), and because only a limited number of patients are diagnosed early enough for successful surgical intervention, 225,000 die. To date, chemotherapy and radiotherapy are only partially and transiently effective. Pancreatitis is life threatening in its acute stage and causes immense and painful suffering in its chronic stages. In the U.S., the number of hospital admissions for pancreatitis is greater than for any other gastrointestinal disease. The Pancreatic Research Program is dedicated to discovering and characterizing the disease mechanisms for pancreatitis so that effective treatments can be developed.
Type 2 diabetes is a worldwide epidemic, with a prevalence reaching 10 percent in many populations. This is especially relevant to research in the Pandol Lab because diabetes underlies the risk of pancreatitis and pancreatic cancer, as well as other cancers and heart disease.
Basic and translational research efforts at the Pancreatic Research Program are designed to advance clinical care delivery to our patients.
The Pandol Laboratory is affiliated with the Pancreatic and Biliary Diseases Program and the Samuel Oschin Comprehensive Cancer Institute.